1995
Gene Therapy Research Unit
Prof Ian Alexander establishes the Gene Therapy Research Unit at Sydney Children’s Hospital at Westmead, a joint initiative of The Children’s Hospital at Westmead and Children’s Medical Research Institute (CMRI).
About VVMF
Australia’s only Viral Vector Manufacturing CDMO
VVMF is a specialist CDMO providing complete life cycle services to the global cell and gene therapy sector. Our capabilities include research, development, and GMP licensed manufacture of viral vectors for advanced therapies.
We combine deep bioprocessing expertise, technology-driven platforms, and flexible development strategies to help customers move efficiently from discovery to manufacturing.
Unlocking the future of medicine
VVMF is based in Sydney and located within the Westmead Health Precinct – Australia’s largest health, education, research, and innovation hub, VVMF is uniquely positioned to accelerate the development of advanced therapies.
We bring deep scientific, technical, and medical expertise from concept to clinic, through the leadership of Chief Medical Officer, Prof. Ian Alexander, gene therapy clinician, and Chief Technology Officer, Prof. Leszek Lisowski, globally recognised vectrologist.
Our platformised process solutions enable rapid access to first-in-human material, while our tailored optimisation services support programs with more complex or bespoke requirements.
Progress to clinic faster
We deliver end-to-end adeno associated viral (AAV) and lentiviral (LV) vector manufacturing with focus on quality and technical excellence.
We help you navigate and access the Australian advantage ecosystem including the R&D tax incentive and clinical trials with our wrap around services.
Our Story
A legacy of innovation, Built for the future
VVMF is the culmination of more than 30 years of pioneering gene therapy research, translational development, and manufacturing expertise established within the Sydney Children’s Hospitals Network at Westmead.
Today, VVMF is building on this legacy to accelerate the development and manufacture of advanced genetic medicines for Australia and the world.
2003
Small-scale facility commissioned within the Kid’s Research Building
Within the Kid’s Research Building, Sydney Children’s Hospitals Network (SCHN)
2019
Seed Funding
Seed funding for the Viral Vector Initiative from the NSW Government
2024
VVMF Established
Funding of $135M approved, company established and CEO appointed
2025
Construction and facility handover
Purpose-built office and laboratories, small-scale, and large-scale manufacturing.
2026
Therapeutic Goods Administration (TGA) issued a Licence to Manufacture Therapeutic Goods (GMP licence).
Our Vision
Unlocking the future of medicine
Mission
To be an Asia-Pacific leader in viral vectors, with global reputation and reach
Our Values
All In, All Together
We’re one team. We back each other, and build together to win together.
Think Big, Be Bold
We’re here to push boundaries, break new ground, challenge norms and each other.
Do the Right Thing - Always
We lead with integrity, own our actions, and hold each other
accountable.
Guided by Science, Fuelled by Impact
We’re here to change lives,
every task, every day, is a step toward something bigger.
Our Leaders
Our Executive Team
- View Bio
Maria Adesida
Chief Quality Officer - View Bio
Prof. Ian Alexander
Chief Medical Officer PhD - View Bio
Anita Balakrishnan
Chief Financial Officer - View Bio
Daniel Clampett
Chief Operating Officer - View Bio
Natasha Daly
Head of Marketing and Communications - View Bio
Karen Edwards
Chief People Officer - View Bio
Prof. Leszek Lisowski
Chief Scientific Officer - View Bio
Vasily Medvedev
Chief Technology Officer - View Bio
Paula Miccinesi
Head of Business Development,
North America - View Bio
Stephen Thompson
Chief Executive Officer - View Bio
Anita van der Meer
Head of Business Development and Partnerships
Our Board
Careers at VVMF
Join the team unlocking the future of medicine
Learn why VVMF was recognised as one of the Best Workplaces in Biotechnology and Pharmaceuticals.
Partner with us to accelerate your path to market
- Explore Our Capabilities
Our Capabilities
- Explore Our Capabilities
End–to–end viral vector
- Explore Our Capabilities
Facilities built for every stage
- Explore Our Capabilities
News
Ready to take the next step?
Learn more about our capabilities, platforms, and our team supporting cell and gene therapy innovators.